Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18671158 | 0.87 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL12391953 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL18591724 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL17552869 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL17552863 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL18591737 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL12262494 | 0.84 | ALDH1A1 (0.37) | KDM4EALDH1A1GAAPOLB | |
| SCHEMBL26159758 | 0.82 | POLB (0.41) | KDM4EALDH1A1POLB | |
| SCHEMBL19592738 | 0.82 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL20128703 | 0.80 | POLB (0.40) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11787903-B2 | Highly strong and tough photo-crosslinked hydrogel material and its preparation and application | ZHONGSHAN GUANGHE MEDICAL TECHNOLOGY CO., LTD (CN) | 2023-10-17 | — | — | US | disclosed |
| US-20230287418-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20160195519-A1 | FLUORESCENT MOLECULAR ROTORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-07-07 | — | — | US | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20110071141-A1 | Pesticidial Condensed-Ring Aryl Compounds | BAYER CROPSCIENCE AG | 2011-03-24 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071141-A1 | Pesticidial Condensed-Ring Aryl Compounds | DDT, PRDX4, CYP4X1 | KDM4E 825/4885ALDH1A1 1268/4885GAA 2327/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | KDM4E 706/4885ALDH1A1 798/4885GAA 1082/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KDM4E 1450/4885ALDH1A1 2211/4885GAA 1274/4885 |
| US-20160195519-A1 | FLUORESCENT MOLECULAR ROTORS | DYNC1LI2, DNAH12, DYNLL2 | KDM4E 4621/4885ALDH1A1 3536/4885GAA 3996/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | KDM4E 669/4885ALDH1A1 2421/4885GAA 3138/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | KDM4E 1076/4885ALDH1A1 4172/4885GAA 350/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | KDM4E 1975/4885ALDH1A1 3735/4885GAA 329/4885 |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | KDM4E 720/4885ALDH1A1 454/4885GAA 4316/4885 |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | KDM4E 4709/4885ALDH1A1 990/4885GAA 2679/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KDM4E 1205/4885ALDH1A1 3688/4885GAA 486/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | KDM4E 1099/4885ALDH1A1 4548/4885GAA 2312/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | KDM4E 4712/4885ALDH1A1 1002/4885GAA 2690/4885 |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | KDM4E 1044/4885ALDH1A1 451/4885GAA 3988/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | KDM4E 498/4885ALDH1A1 3412/4885GAA 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.